The patient, who was initially treated only with the closed-loop insulin infusion system (with a predictive algorithm protecting against hyperglycemia and hypoglycemia), was prescribed tirzepatide due to the concomitant presence of class 1 obesity (BMI: 32.2 kg/m2) associated with poorly controlled diabetes (HbA1c: 9.4%). The gene discussed is INS; the disease is obesity disorder.